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ABSTRACT
A high prevalence of diabetes mellitus (DM) represents a challenge during the coronavirus 
disease 2019 (COVID-19) pandemic. DM represents an important risk factor for adverse 
outcomes in patients with COVID-19. Objective: to describe the clinical, epidemiological 
and molecular characteristics; including treatment options among patients with COVID-19 
and diabetes mellitus. Method: a literature review was conducted in articles published by 
peer-reviewed journals up to June 2020. SciELO and PubMed databases were screened 
in search of articles. The search terms included diabetes mellitus, coronavirus infection, 
and its Spanish translation “diabetes mellitus”, “infección por coronavirus”. Development: 
COVID-19 and diabetic patients may be predisposed to immune dysfunction that results 
in severe late illness. Most patients with mild infection can continue with the usual 
antihyperglycemic medications. The result of the use of corticosteroids is not yet clear. There 
are safety concerns regarding treatment with chloroquine/hydroxychloroquine, due to its 
hypoglycemic role and adverse effects. Conclusions: the molecular and pathophysiological 
mechanisms between COVID-19 and diabetes mellitus are still not fully understood. The poor 
prognosis observed in these patients requires the creation of a novel treatment protocol.
RESUMEN
Introducción: una alta prevalencia de la diabetes mellitus representa un desafío durante 
la pandemia de la enfermedad por coronavirus 2019 o COVID-19. La diabetes mellitus 
constituye un importante factor de riesgo de complicaciones en pacientes con COVID-19. 
Objetivo: describir las características clínicas, epidemiológicas y moleculares; así como 
opciones de tratamiento en los pacientes con COVID-19 y diabetes mellitus. Método: se 
realizó una revisión bibliográfica en artículos publicados en revistas biomédicas revisadas 
por pares hasta junio de 2020. Se revisaron las bases de datos SciELO y PubMed. Los 
términos de búsqueda incluyeron diabetes mellitus, coronavirus infection, y su traducción 
al español «diabetes mellitus», «infección por coronavirus». Desarrollo: La COVID-19 y los 
pacientes diabéticos pueden estar predispuestos a una disfunción inmunológica que resulta 
en una enfermedad tardía severa. La mayoría de los pacientes con infección leve pueden 
continuar con los medicamentos anti-hiperglucémicos habituales. El resultado del uso de 
corticoesteroides aún no está claro. Existen preocupaciones de seguridad con respecto al 
tratamiento con cloroquina/hidroxicloroquina, en relación con su función hipoglucémica y 
demás efectos adversos. Conclusiones: los mecanismos moleculares fisiopatológicos entre 
la COVID-19 y la diabetes mellitus todavía no están del todo dilucidados. El mal pronóstico 
que se observa en pacientes con ambas enfermedades requiere la creación de nuevos 
protocolos de tratamiento. 
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INTRODUCTION
Since December 2019 China experienced an outbreak of 
pneumonia, caused by a novel coronavirus officially named 
as Severe Acute Respiratory Syndrome Coronavirus-2 
(SARS-CoV-2), by the International Committee on 
Taxonomy of Viruses (ICTV)(1). Coronaviruses (CoVs) are 
enveloped viruses with a single-stranded, positive-sense 
RNA genome and commonly linked to human respiratory 
infections. In most immunocompetent patients, CoVs 
infection leads to mild upper respiratory infection(2).  
Coronavirus disease 2019 (COVID-19), caused by SARS-
CoV-2, converted to pandemic within a few months after 
the first reported case in Hubei province, China(3). On 
June 21st, 2020, 185 countries affected with COVID-19 
confirmed 8 796 469 cases and 464 294 deaths for a 
mortality rate of 5,28 %. In the Americas, a report of 4 
374 446 confirmed cases reached 49,73 % of all cases 
worldwide, with 221 783 deaths and a mortality rate 
of 5,07 %. Cuba reported 2 315 positive cases, with an 
increased incidence of the male gender, and 85 confirmed 
deceased(4). 
During COVID-19 pandemic, the high prevalence of 
metabolic diseases has become a challenge to achieve 
stability in infected patients. DM represents one of these 
diseases and the risk of severity of COVID-19 increases 
to the undiagnosed patients or with inadequate 
glycemic control. Although that the literature reports an 
increase in COVID-19 cases with comorbidities such as 
obesity, hypertension, and diabetes, the role of these 
comorbidities in patients infected with SARS-CoV-2 has 
not yet been explored(5). 
Studying the behaviour of COVID-19, it has been 
observed that DM together with the elderly have become 
risk factors that lead to unfavourable prognoses of the 
disease. About 20% of admissions to intensive care units 
(ICU) are attributed to DM, according to reports from a 
small cohort study in Wuhan. Also, Italy has reported that 
two-thirds of those who died from the novel coronavirus 
had a past medical history of diabetes mellitus(6).
Middle East Respiratory Syndrome (MERS) outbreak that 
mainly affected Saudi Arabia in 2012, the relationship of 
complications of patients with diabetes and this disease 
can also be evidenced(7). 
Several studies report the severity of COVID-19 in diabetic 
patients, although the reason for this severity and the 
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effect of hyperglycemia in the course of the SARS-
CoV-2 disease is still not well understood, even though 
that diabetics are at higher risk of respiratory infections 
because the immune system is compromised(8).
Increased awareness of the clinical features, 
pathophysiology, and potential mechanisms that 
increase the risk is needed to provide better care and 
spur new investigations, both basic and clinical, to better 
understand COVID-19 in patients with DM(2). 
The objective of this review is to describe the clinical, 
epidemiological and molecular characteristics; including 
treatment options among patients with COVID-19 and 
diabetes mellitus.
METHOD
A literature review was conducted in articles published 
by peer reviewed journals up to June 21st, 2020. SciELO, 
Pubmed/Medline, The Lancet, and Nature Reviews 
Endocrinology were screened in search for articles. The 
search terms included diabetes mellitus, coronavirus 
infection, and its Spanish translation “diabetes mellitus”, 
“infección por coronavirus”. Twenty articles of interest 
were included in this research.
DEVELOPMENT
Most people with COVID-19 have a disease incubation 
period of 2 to 14 days and will experience cough, 
fever, shortness of breath or less commonly, nausea 
and diarrhoea. A late phase of sudden deterioration is 
observed in some patients after 7–10 days of fever, and 
deterioration in oxygen saturation(3). 
Patients with diabetes develop similar symptoms, but 
less specific symptoms are also developed, fever may 
be less common, and deterioration could occur rapidly 
in later stages. A deteriorated glycemic control and 
hyperglycemic emergencies in those with type 1 diabetes 
may be the initial presentation of diabetic ketoacidosis 
(DKA)(3). The available information does not indicate 
increased susceptibility to coronavirus infections in 
children or adults with type 1 diabetes (T1D)(8). 
Alterations in laboratory markers and CT imaging 
Zhang Y et al.(1) found that COVID-19 patients had a 
relatively high proportion (24%) of diabetes, and proved 
that diabetes was associated with alterations in laboratory 
markers, corresponding to a severer clinical subtype at
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presentation, and poorer prognosis compared to those 
without diabetes after SARS-CoV-2 infection.
The diabetic COVID-19 patients had a higher median 
leucocytes number (6.34[IQR: 4.66, 8.15] vs. 5.45[IQR: 
4.31, 7.19], P=0.039) and median neutrophils numbers 
(4.49[IQR: 3.12, 6.91] vs. 3.82[IQR: 2.81, 5.39], P=0.022) 
compared with non-diabetic patients. COVID-19 patients 
with diabetes had more leucocytes increase (20.6% vs. 
6.7%) but less leucocytes decrease (4.8% vs. 10.3%, 
P=0.004) than those patients without DM. The neutrophil-
to-lymphocytes ratio (NLR) was significantly higher in 
diabetic patients compared to those without diabetes 
(median: 4.56[IQR: 2.69, 9.51] vs. median: 3.8 [IQR: 2.25, 
6.31], P=0.043)(1). 
Elevated serum ferritin, lactate dehydrogenase, 
C-reactive protein (CRP), procalcitonin and erythrocyte 
sedimentation rate (ESR) predicted severe disease 
among patients with COVID-19 and DM; a possible 
explanation of secondary bacterial infection intensifying 
COVID-19. Increased serum ferritin, could predict a severe 
secondary bacterial infection among these patients(3). 
Lymphopenia was also associated with severe 
conditions in patients with COVID-19. DM, it’s related 
with a proinflammatory homeostatic immune response, 
skewed toward helper T cell 1 (Th1) and T17 cells 
and a decrease in regulatory T cells (Treg). Immune 
dysfunction of diabetes alone or following infection 
has been reported for a wide variety of immune cells, 
not just macrophages, monocytes and CD4+ T cells(1). 
Raised D-dimer levels were observed in severe illness, 
suggesting a possible consumptive coagulopathy, while 
anticoagulation was linked to the decreased mortality 
rate in COVID-19 patients(3).
The COVID-19 in its severe forms is a state of severe 
inflammation and thrombotic tendency, and diabetic 
patients may be predisposed to an intense immune 
dysfunction as a cause of severe late illness. This is further 
supported by renal and cardiovascular comorbidities, 
which added to the proinflammatory state, increase the 
tendency to complications(3).
Elevated N-terminal pro-brain-type natriuretic peptide 
(NT-proBNP) and cardiac troponin I (cTnI), were 
significantly correlated with severe disease. The 
COVID-19 may lead to myocardial injury and impair 
cardiac function. In people with diabetes and preexisting 
ischemic heart disease, the limited cardiac reserve may 
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increase morbidity and mortality risk(3). 
Reports informed that intensive care unit (ICU) patients, 
non-ICU patients and recovery patients differ in 
computed tomography imaging results, which means CT 
results is an indicator to determine the severity of SARS-
CoV-2 pneumonia. According to the quantifiable score 
(15 vs. 10 p=0.04), the diabetes group presented higher 
CT imaging score compared with the non-diabetes 
group, which means pneumonia in diabetic patients is 
more severe than non-diabetic patients(9).
Risk factors
Clinical medication determined that the increased insulin 
dose after infection by SARS-CoV-2 proved that the virus 
has an impact on the patient’s glucose metabolism. 
Dysregulation of glucose metabolism aggravates DM 
and them affect the severity of pneumonia(9).
Two or more comorbidities in addition to age, it is 
common to find in diabetic patients, which increase the 
risk of SARS-CoV-2. However, a study in China of 1 590 
patients with COVID-19 found that DM is an independent 
risk factor for the increase in admission of cases to ICU, 
with the need for mechanical ventilation and possible 
death (HR 1.59; 95% CI 1, 03-2.45; p = 0.037). However, 
there are no publications that report on the severity in 
patients with type 1 diabetes, although experts comment 
that it maintains similar behaviours(3).
Aggravating molecular mechanisms
Increased susceptibility concerning COVID-19 in patients 
with DM is promoted by higher affinity cellular binding 
and efficient virus entry, decreased viral clearance, 
diminished T cell function, increased susceptibility to 
hyperinflammation including cytokine storm syndrome, 
and presence of cardiovascular diseases(2).
Kumar-Singh et al.(10) in a study of 161 patients with 
COVID-19 in Wuhan observed increased time for viral 
clearance to 25 days in patients with diabetes. Apart from 
the usual mechanisms of impaired neutrophil chemotaxis 
and phagocytosis predisposing to infections, there are 
several specific factors responsible for increased risk 
and severity of infection by SARS-CoV-2 among diabetes 
patients. 
DM is associated with reduced expression of 
angiotensin-converting enzyme 2 (ACE-2). Under normal 
physiological conditions, ACE-2 degrades angiotensin-II 
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including a little extent angiotensin-I to smaller peptides. 
The pulmonary ACE-2/angiotensin system plays a potent 
anti-inflammatory and anti-oxidant role and ACE-2 is 
known to be protective against lethal avian influenza 
A H5N1 infection. Accordingly, low ACE-2 expression 
in DM might explain the increased incidence of severe 
lung injury and acute respiratory disease syndrome with 
COVID-19, in addition to other factors(11).
Increased expression of ACE-2-receptor in renal cortex, 
liver and pancreas have been found in diabetic mice, but 
not in lungs. A phenome-wide Mendelian randomization 
study found diabetes to be casually related to ACE-
2 expression. Though the significance of these 
observations is not clear at present, increased ACE-2 
expression might predispose patients with diabetes to 
infection with SARS-CoV-2(10).
The use of angiotensin-converting enzyme inhibitors 
(ACEi) or angiotensin-receptor blockers (ARBs) is 
associated with increased expression of ACE-2-receptor 
as an adaptive response to counteract the elevated levels 
of angiotensin-II. Unfortunately, SARS-CoV-2 uses ACE-
2-receptor to entry into the host pneumocytes, thus, 
ACE-2-receptor upregulation would facilitate entry and 
subsequent proliferation of the coronavirus(11).
DM is associated with an increase in furin, which is a type-
1 membrane-bound protease, that belongs to the protein 
convertase subtilisin/Kexin family (PCSK). It is involved 
in coronaviruses entry into the cell and increased furin 
has been reported in diabetes, which might facilitate 
viral replication(10).
Effects in white blood cells
Alterations in CD4 lymphocytes have been reported in 
animal models with MERS. Lymphocytopenia is observed 
in patients with COVID-19 and also correlated with poor 
prognosis(10).
DM inhibits neutrophil chemotaxis, phagocytosis, 
and intracellular killing of microbes. Impairments in 
adaptive immunity characterized by an initial delay in 
the activation of Th1 cell-mediated immunity and a 
late hyperinflammatory response is often observed in 
patients with diabetes(2). 
Several cytokines are increased in COVID-19 infection. 
Amongst these, IL-6 is increased in diabetes and may 
play a more deleterious role in COVID-19 infection.
Testing monoclonal antibody against IL-6 receptor 
(tocilizumab) could represent a treatment option in 
COVID-19 patients(10). 
ACE-2 receptors are expressed in pancreatic islets and 
infection with SARS-CoV it is linked to hyperglycemia 
in people without preexisting diabetes. Hyperglycemia 
persisted in some cases for 3 years after recovery from 
SARS indicating transient damage to beta cells. This 
effect still up to date, not reported in COVID-19, however, 
it is important to monitor blood glucose levels in the 
acute stage and during follow up of the disease(10). 
A recent publish preprint established that non-
structural proteins of SARS-CoV-2 attack the B1-chain 
of haemoglobin leading to dissociation of iron from 
porphyrin and impairing the ability of haemoglobin 
to transport oxygen. Although just a hypothesis, 
SARS-CoV-2 might have a higher affinity to glycated 
haemoglobin than non-glycated haemoglobin(11). Future 
research should focus on describing the interaction of 
SARS-CoV-2 and glycated haemoglobin.
Dipeptidyl peptidase-4 (DPP4)
Dipeptidyl peptidase-4 (DPP4) is a tissue oligopeptide 
involved in multiple biological processes that include 
control of the activity of growth factors, chemokines 
and bioactive peptides included T-cell activation besides 
regulating glucose metabolism(10).
DPP4 serves as the receptor for MERS-CoV, in the 
same way as ACE-2 is the receptor for SARS-CoV and 
SARS-CoV-2. Experimental studies have suggested that 
certain changes in DPP-4 are associated with a reduced 
risk of MERS-CoV infection. This finding might explain 
the absence of MERS-CoV cases in Africa, despite the 
presence of the virus in camels, probably related to the 
frequent presence of protective polymorphisms of DPP-
4 in Africans. Moreover, this has generated an immense 
interest whether to use DPP4 inhibitors (DPP4i) to reduce 
the viral entry of MERS-CoV. In one in vitro study, 
sitagliptin, vildagliptin and saxagliptin could not block 
the coronavirus entry into cells(10).
Though ACE-2 is recognized as the main receptor for 
SARS-CoV-2, a recent modelling study did not rule out 
its interaction with CD26 or DPP4. Moreover, a possible 
interaction of DPP4 and renin-angiotensin system (RAS) 
pathways seems to be plausible, although not completely 
studied. Interestingly, dipeptidyl amino-peptidase I-III 
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cleaves the Angiotensin II to Angiotensin III and IV which 
has cascading favourable effect through Angiotensin-4 
(AT-4) receptors. Similarly, various endo- and oligo-
peptidase cleaves Angiotensin I directly to Angiotensin 
which has a very favourable cascading effect. This 
suggests that a plausible interaction of non-specific DPP-
4i with ACE-2 is theoretically possible, and therefore, this 
area needs future research(10). 
Some of the studies found that co-administration of 
angiotensin-converting enzyme inhibitors (ACE-I) 
including DPP4 inhibitors led to an increased sympathetic 
tone and a consequent adverse hemodynamic effect. 
There has been an interaction observed between ACE-I 
and vildagliptin where a 4- to 5-folds increased risk of 
angioedema was noted, possibly due to the diminished 
degradation of bradykinin or substance P. In contrast, 
in the experimental study, sitagliptin was shown to 
inhibit ACE which could partially explain the purported 
beneficial cardiovascular effects(10). 
DPP4 inhibitors are associated with an increased risk of 
upper respiratory infections, however, these agents did 
not show a lead to increased risk of pneumonia. There 
still insufficient evidence either for or against the use of 
DPP-4i in patients with diabetes and COVID-19(10).
Considerations of DM treatment in pandemic
At current times, treatment of diabetes has become a 
challenge because of the alterations in daily routine affect 
the dietary intake as well, regular walks and visits to the 
gym are limited, and the unpredictability of the disease 
increases mental stress too. Glucose dysregulation 
is caused by these factors and could predispose the 
patients to ketoacidosis, hyperosmolar coma, infections 
and even acute cardiac events (1,10).
Standardization of research protocols and identification 
of research priorities is essential to use time and resources 
productively. It is needed urgent steps to answer critical 
questions in the prevention and management of diabetic 
patients with COVID-19. 
Insulin is extensively used to control glucose in critically 
ill hospitalized patients with diabetes, and the emerging 
use of continuous glucose monitoring may lower the 
rates of hypoglycemia associated with insulin use in 
the hospital, including in some patients with a critical 
illness(8, 10).
Amongst available agents for the treatment of acute 
illness complicated by diabetes, insulin is the most 
extensively used agent in human subjects with bacterial 
or viral infections and hospitalized critically ill patients. 
However, there is little information surrounding potential 
benefits or risks of insulin in the context of acute 
coronavirus infection(8,10). 
Intravenous insulin infusion is requiring in patients 
on mechanical ventilation or with poor oral intake. 
The medical personnel are exposed to the virus with 
every visit to the patients to adjustment infusion rates, 
so is a need to make alternatives strategies of insulin 
administration. The use of subcutaneous short-acting 
insulin analogues is one of these strategies, but its safety 
in critically ill patients is less clear. A single dose of basal 
insulin has been an attempt in critically ill patients as in 
one study from Thailand(10).
In patients with type 1 diabetes with COVID-19 and 
hyperglycemia, it is important to monitor the blood 
glucose and ketone levels, maintain hydration and 
continue insulin therapy(8,10).
Most patients with mild infection and normal oral intake 
can continue the usual antihyperglycemic medication. 
Metformin should be used with caution in unstable 
hospitalized patients and should be discontinued in 
people with concomitant sepsis or severe impairment of 
hepatic and renal function. In severe COVID-19 infection, 
the hypoxia state may further increase the risk of lactic 
acidosis(3,8). Further research is needed regarding the 
role of metformin as a host-directed treatment for severe 
COVID-19.
GLP-1R agonists have been explored as glucose-lowering 
agents in the perioperative period and the intensive care 
unit, and have generally been proven safe and effective 
for blood glucose management. However, the total 
number of subjects studied is small and the duration of 
therapy is limited. Although GLP-1 safely lowers blood 
glucose in short term studies of ventilated patients with 
a critical illness, there is insufficient experience with 
the safety and use of GLP-1R agonists in critically ill 
subjects to make therapeutic recommendations for use 
of these agents in the context of coronavirus infection 
and exenterate-based formulations should be stopped in 
subjects with deteriorating kidney function(8). 
Sulfonylureas increase the risk of hypoglycemia and are 
best avoided in hospitalized subjects with severe medical 
illness. Although SGLT2 inhibitors are generally well-
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tolerated in the outpatient setting, and cardioprotective 
most notably in the context of heart failure, SARS-CoV-2 
infection may be associated with anorexia, dehydration, 
and rapid deterioration in clinical status. Hence, 
symptomatic individuals with T2D and active SARS-CoV-2 
infection may be at heightened risk for volume depletion 
and euglycemic ketoacidosis. Accordingly, the available 
evidence suggests re-evaluation or discontinuation of 
these agents in very unwell ambulatory individuals, and 
the SGLT2 inhibitors should be routinely discontinued 
in unstable patients with severe SARS-CoV-2 infection 
upon admission to hospital(8). 
To date, neither benefit nor harm has been shown 
in humans on DPP4 inhibitors during CoV infections. 
Therefore, DPP4 inhibitors could be continued, at least 
in mild cases of COVID-19, while potential benefit in 
treating CoV infection remains to be studied further. 
Similarly, GLP-1RAs are known to have anti-inflammatory 
effects and have shown potential for therapeutic benefit 
in acute lung injury. The available evidence is insufficient 
to determine the impact, if any, of sustained partial 
reduction of DPP4 activity, as achieved clinically in 
subjects with T2D treated with DPP4 inhibitors, on clinical 
outcomes in humans with active coronavirus infection(8). 
Although glucocorticoids are used in the treatment of 
severe acute respiratory distress syndrome (ARDS), 
data for their use in ARDS caused by viral pneumonia 
are minimal and therefore they are not recommended for 
routine use in COVID-19. The place of glucocorticoids in 
the treatment of COVID-19 is being investigated. If they 
are used in patients with diabetes, hyperglycemia may 
worsen, necessitating escalation of insulin therapy(12). 
The usage of cortisone had unexpectedly a negative effect 
on the process of viral clearance, although cortisone was 
commonly used in SARS patients. However, cortisone 
was targeted at particularly severe cases, which may 
have confounded the results. Compared to SARS, the 
outcome of using corticosteroids in COVID-19 patients 
is still unclear. Given that corticosteroids as immune-
modulators that can decline circulating specific B- and 
T-cell subsets(12). 
Treatment basis of COVID-19 patients with DM
Immunomodulators Cytokine release syndrome (‘cytokine 
storm’) is thought to be central to the pathogenesis 
of rapid deterioration and multi-organ dysfunction in 
patients with COVID-19. Therefore, immunomodulatory 
agents are postulated to be of benefit (13,14). 
There are specific safety concerns for people with 
diabetes, as hypoglycemia is a known adverse effect of 
chloroquine / hydroxychloroquine treatment. 
Suggested mechanisms are decreased intra-cellular 
insulin degradation, increased insulin-mediated glucose 
transport, increased insulin release and enhanced insulin 
sensitivity. Extra caution is required when is used with 
other glucose-lowering agents and dose reduction may 
become necessary (13,14,15). 
It is very important to continue with an appropriate 
antihypertensive and lipid-lowering regime in these 
patients because most type 2 diabetic have other 
components of the metabolic syndrome such as 
hypertension and dyslipidaemia(15).
Statins reduce the expression of ACE-2-receptor 
induced by high lipids such as low-density lipoprotein or 
lipoprotein (a). The pleiotropic anti-inflammatory effects 
of statins have been attributed to the upregulation of 
ACE-2-receptor(16). However, although it is believed that 
modulation of ACE-2 expression is associated with both 
infection and mortality rates in COVID-19, statins should 
not be discontinued because of the long-term benefits 
and the potential for tipping the balance towards a 
cytokine storm by rebound rises in interleukin(IL)-6 
and IL-1B. Given the close links between diabetes and 
cardiovascular disease, the authors recommend control 
of lipid concentrations in all patients with COVID-19(17,18).
There is a hypothesis that increased ACE-2 expression 
could increase viral binding and entry into the cell, 
but there isn’t clinical evidence to support this. 
Although, ACE inhibitor and ARBs increase the levels 
of ACE-2 by inhibiting the conversion of angiotensin1 to 
angiotensin2(18,19).
In patients with pneumonia, some articles have reported 
that calcium channel blockers (CCB) reduce the severity 
of disease and mortality. It seems safe to continue the 
administration of this drug in hypertensive patients, but 
the role of CCB in COVID-19 has not been studied(10).
Aspirin has anti-inflammatory properties, is advisable 
to discontinue in patients with sepsis and disseminated 
intravascular coagulation. However, in patients 
with underlying coronary artery disease, it needs 
to be continued as anticoagulant unless otherwise 
contraindicated(10,19,20).
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CONCLUSIONS
The molecular and pathophysiological mechanisms 
between COVID-19 and diabetes mellitus are still not 
fully understood. Due to the poor prognosis that has 
been observed, the creation of treatment protocols for 
COVID-19 patients with a past medical history of diabetes 
mellitus is crucial, although it is for expert consideration 
depending on the characteristics and evolution of 
each patient. Diabetes prevention and control actions 
are a cornerstone to obtain better results when facing 
COVID-19.
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